Splicing in oncogenesis and tumor suppression

Post‐transcriptional modifications, such as 5′ end capping, 3′ end polyadenylation and splicing, are necessary for the precise regulation of gene expression and transcriptome integrity. Therefore, it is not surprising that abnormalities of these post‐transcriptional modifications prompt numerous diseases, including cancer. In fact, many studies revealed that misregulation of mRNA processing, especially splicing, are observed in a variety of cancer cells. In this review we describe how changes within RNA splicing regulatory elements or mutations in the processing factors alter the expression of tumor suppressors or oncogenes with pathological consequences. In addition, we show how several small molecules that bind to spliceosomal components and splicing regulators inhibit or modulate splicing activity. These compounds have anticancer activity and further development of small molecule modulators has potential in next generation cancer therapy.

[1]  L. Naldini,et al.  RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. , 1994, The EMBO journal.

[2]  S. Kojima,et al.  Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF , 2010, Cancer science.

[3]  M. Ladomery,et al.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors , 2008, Journal of Cell Science.

[4]  M. Moore,et al.  The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing , 2008, Journal of Biological Chemistry.

[5]  S. Horinouchi,et al.  Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. , 2011, ACS chemical biology.

[6]  L. Trusolino,et al.  Invasive growth: from development to metastasis. , 2002, The Journal of clinical investigation.

[7]  C. Chalfant,et al.  The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x , 2007, The Journal of cell biology.

[8]  M. Herlyn,et al.  Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Johanne Toutant,et al.  Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. , 2003, Cancer research.

[10]  N. Mulherkar,et al.  MADD/DENN Splice Variant of the IG20 Gene Is a Negative Regulator of Caspase-8 Activation , 2007, Journal of Biological Chemistry.

[11]  N. Ferrara.  Role of vascular endothelial growth factor in regulation of physiological angiogenesis. , 2001, American journal of physiology. Cell physiology.

[12]  T. Yamori,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. , 2004, The Journal of antibiotics.

[13]  T. Zhukov,et al.  Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  M. Matsufuji,et al.  Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. I. Taxonomy, fermentation, isolation and screening. , 2004, The Journal of antibiotics.

[15]  J. Jessee,et al.  Neoplastic Transformation and Tumorigenesis Associated with Sam68 Protein Deficiency in Cultured Murine Fibroblasts* , 2000, The Journal of Biological Chemistry.

[16]  M. Okuhara,et al.  New Antitumor Substances, FR901463, FR901464 and FR901465 , 1996 .

[17]  P. Comoglio,et al.  A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype , 1996, Molecular and cellular biology.

[18]  M. Steinmetz,et al.  Structure of a VEGF–VEGF receptor complex determined by electron microscopy , 2007, Nature Structural &Molecular Biology.

[19]  A. Krainer,et al.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene , 2007, Nature Structural &Molecular Biology.

[20]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[21]  C. Thompson,et al.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Mulshine,et al.  Differential Expression of the Early Lung Cancer Detection Marker, Heterogeneous Nuclear Ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in Normal Breast and Neoplastic Breast Cancer , 2001, Breast Cancer Research and Treatment.

[23]  P. Brousset,et al.  Predominant expression of the long isoform of Bcl‐x (Bcl‐xL) in human lymphomas , 1996, British journal of haematology.

[24]  H. Lehrach,et al.  No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis , 2011, Oncotarget.

[25]  D. Andrews,et al.  Apoptosis: embedded in membranes. , 2010, Current opinion in cell biology.

[26]  C. Ng,et al.  Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. , 2009, The Journal of clinical endocrinology and metabolism.

[27]  Auinash Kalsotra,et al.  Functional consequences of developmentally regulated alternative splicing , 2011, Nature Reviews Genetics.

[28]  H. Takebe,et al.  FERMENTATION , ISOLATION , PHYSICO-CHEMICAL PROPERTIES AND BIOLOGICAL ACTIVITIES , 2006 .

[29]  D. Bates,et al.  Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma , 2007, British Journal of Cancer.

[30]  J. Valcárcel,et al.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.

[31]  Marina Ziche,et al.  VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant , 2004, Cancer Research.

[32]  Y. Mizui,et al.  Biological validation that SF3b is a target of the antitumor macrolide pladienolide , 2011, The FEBS journal.

[33]  Luigi Coppola,et al.  Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. , 2011, Cancer research.

[34]  C. Will,et al.  The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.

[35]  M. Assanah,et al.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.

[36]  D. Shalloway,et al.  Sam68 exerts separable effects on cell cycle progression and apoptosis , 2004, BMC Cell Biology.

[37]  M. Minden,et al.  Myelodysplastic syndromes: the complexity of stem-cell diseases , 2007, Nature Reviews Cancer.

[38]  C. Brennan,et al.  Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas , 2011, The EMBO journal.

[39]  Hongwei Lu,et al.  Relevance of Bcl-x expression in different types of endometrial tissues , 2010, Journal of experimental & clinical cancer research : CR.

[40]  M. Hagiwara,et al.  Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.

[41]  Robert Wechsler-Reya,et al.  BIN1 is a novel MYC–interacting protein with features of a tumour suppressor , 1996, Nature Genetics.

[42]  Hiroshi Kimura,et al.  Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks* , 2004, Journal of Biological Chemistry.

[43]  John Calvin Reed,et al.  Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. , 1997, British Journal of Cancer.

[44]  N. Mulherkar,et al.  IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC , 2004, Oncogene.

[45]  G. Dreyfuss,et al.  Messenger-RNA-binding proteins and the messages they carry , 2002, Nature Reviews Molecular Cell Biology.

[46]  B. Frey,et al.  Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing , 2008, Nature Genetics.

[47]  J. Cáceres,et al.  The SR protein family of splicing factors: master regulators of gene expression. , 2009, The Biochemical journal.

[48]  B. Blencowe,et al.  Identification and characterization of RED120: A conserved PWI domain protein with links to splicing and 3′‐end formation , 2007, FEBS letters.

[49]  S. Harper,et al.  Activity Coreceptor Binding and Deficient Regulation of Kinase Agonist for VEGF Receptor-2 Due to Lack of In vitro Vascular Endothelial Growth Factor ( VEGF )-A 165 b Is a Weak , 2008 .

[50]  D. Shalloway,et al.  An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis , 1994, Nature.

[51]  Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia , 2011 .

[52]  Lili Wan,et al.  RNA and Disease , 2009, Cell.

[53]  Eric T. Wang,et al.  Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.

[54]  C. Ford.  Prospective Detection of Preclinical Lung Cancer : Results from Two Studies of Heterogeneous Nuclear Ribonucleoprotein A 2 / B 1 Overexpression , 2000 .

[55]  M. Hentze,et al.  NMD: RNA biology meets human genetic medicine. , 2010, The Biochemical journal.

[56]  J. Hsuan,et al.  A target for Src in mitosis , 1994, Nature.

[57]  Steven J. Harper,et al.  VEGF-A splicing: the key to anti-angiogenic therapeutics? , 2008, Nature Reviews Cancer.

[58]  Or Gozani,et al.  A Potential Role for U2AF-SAP 155 Interactions in Recruiting U2 snRNP to the Branch Site , 1998, Molecular and Cellular Biology.

[59]  Michael R Green,et al.  Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.

[60]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[61]  R. Reed,et al.  The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region. , 2011, Genes & development.

[62]  M. Okuhara,et al.  New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. , 1996, The Journal of antibiotics.

[63]  Johanne Toutant,et al.  Heterogeneous Nuclear Ribonucleoprotein K Represses the Production of Pro-apoptotic Bcl-xS Splice Isoform , 2009, The Journal of Biological Chemistry.

[64]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[65]  E. Benz,et al.  Novel Splicing Factor RBM25 Modulates Bcl-x Pre-mRNA 5′ Splice Site Selection , 2008, Molecular and Cellular Biology.

[66]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[67]  J. Dick,et al.  A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Manley,et al.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. , 2010, Genes & development.

[69]  T. Owa,et al.  Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.

[70]  C. Sette,et al.  The RNA-binding protein Sam68 is a multifunctional player in human cancer. , 2011, Endocrine-related cancer.

[71]  Melissa J. Moore,et al.  Pre-mRNA Processing Reaches Back toTranscription and Ahead to Translation , 2009, Cell.

[72]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[73]  L. Shkreta,et al.  hnRNP proteins and splicing control. , 2007, Advances in experimental medicine and biology.

[74]  B. Séraphin,et al.  The U1 snRNP-associated factor Luc7p affects 5′ splice site selection in yeast and human , 2007, Nucleic acids research.

[75]  Sejeong Shin,et al.  Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt–dependent matrix metalloproteinase-9 expression , 2006, Molecular Cancer Therapeutics.